3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 来源：新浪证券-红岸工作室 1月5日，采纳股份涨11.05%，成交额1.61亿元，换手率7.53%，总市值35.38亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 该股筹码平均交易成本为27.80元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近压力位 29.73，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公司简介 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分 ...

三、经常开窗通风 佩戴口罩请注意"五要五不要"： （五）要选择适合自己脸型的口罩，出现呼吸道症状时不要佩戴带呼吸阀的口罩。 二、保持手部卫生 勤洗手是切断病毒传播的重要环节。建议使用流动水和肥皂洗手，或使用含酒精的免洗消毒液。避免用 未清洁的手触摸眼、鼻、口等部位。 今天，上海市卫生健康委发布消息：根据全市公立医疗机构监测数据显示，目前，全市各级公立医疗机 构急诊和发热门诊就诊量较12月初有所下降，各项服务开展平稳有序。其中儿科医疗服务供给充分，急 诊和发热门诊每日平均候诊时间基本都控制在30分钟内。 市卫健委提醒，目前本市处在流感流行季，虽然近期疫情总体平稳，但流感病毒活动强度仍处于全年较 高水平。甲型H3N2流感病毒仍是主要流行株。 冬季是流感等呼吸道传染病高发季节，为保障您和家人健康，建议做好以下个人和家庭防护措施： 一、科学佩戴口罩 佩戴口罩是预防呼吸道传染病传播的有效手段，尤其在人群密集、空气流通较差的公共场所。元旦、春 节出行或前往车站、医院、商场、影院等场所时，请全程规范佩戴口罩。 （二）家人患呼吸道疾病时，照护者应注意个人防护（如佩戴口罩、洗手），并对常用物品和环境进行 清洁消毒，降低家庭内传 ...

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.84% on December 23, with a trading volume of 55.21 million yuan and a market capitalization of 3.246 billion yuan [1] Group 1: Company Overview - Canar Medical, established on July 23, 2004, is located in Jiangyin, Jiangsu Province, and was listed on January 26, 2022 [7] - The company specializes in the research, production, and sales of medical and veterinary injection and puncture instruments, as well as laboratory consumables [7] - The main revenue sources for Canar Medical are syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86% [7] - The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Position and Trends - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproductive technology sector [2] - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [3] - The stock has seen a recent decrease in major shareholder holdings, with a net outflow of 4.40 million yuan on the day of analysis [4][5]

Group 1 - The article highlights the increased risk of influenza transmission due to sudden temperature drops and crowded indoor environments, emphasizing the importance of daily protective measures in densely populated places like schools and nursing homes [1] Group 2 - Influenza is characterized as an acute respiratory infectious disease caused by the influenza virus, with symptoms that can include high fever, headaches, muscle and joint pain, and fatigue, distinguishing it from the common cold which typically has milder symptoms [2] - Severe complications from influenza can include pneumonia, heart damage, and shock, with vulnerable groups such as the elderly, chronic disease patients, children, and pregnant women being at higher risk for serious outcomes [2] Group 3 - Basic preventive measures against influenza include frequent handwashing, especially after contact with public items and before meals, using running water and soap for at least 20 seconds [3] - In high-risk environments or when in contact with individuals showing respiratory symptoms, proper mask-wearing is advised [3] Group 4 - Masks should not be used continuously and must be replaced immediately if they become wet or contaminated [4] - Coughing or sneezing should be covered with a tissue or the elbow to prevent droplet transmission, with used tissues disposed of promptly and hands washed afterward [4] Group 5 - It is recommended to maintain warmth while ensuring daily ventilation of indoor spaces 2-3 times for over 30 minutes each time to keep air circulation [5] Group 6 - A balanced diet rich in proteins, vitamins, and minerals is essential for building internal immunity, along with moderate exercise and ensuring 7-8 hours of quality sleep each night [6] - Foods such as water chestnuts, lilies, lotus root, snow pears, tremella, and yam are suggested, with herbal teas like honeysuckle and chrysanthemum being beneficial for throat discomfort [6]

如果咳嗽持续加重，同时伴有其他症状，比如胸痛、气短、胸闷，影响正常的生活和工作了，建议一定 要及时去医院就诊。 高峰表示，冬至数九，天气寒冷干燥，呼吸道的防御功能也会下降，很容易发生像感冒、肺炎、流感等 呼吸道感染性疾病，还有一些有慢性呼吸系统疾病的，像有哮喘、慢阻肺的这种人，也容易在这个季节 因为感冒而诱发基础疾病的加重。推荐一个中医预防感冒的小方法，即坚持晨起用凉水清洗鼻翼两侧， 然后以手指按压鼻翼外缘中点旁开0.5寸的位置——迎香穴，按压迎香穴至微微发热，这样可以增加呼 吸道的防御功能，同时也改善鼻部对寒冷空气的适应力，起到预防感冒的作用。同时，提醒有慢性疾病 的患者，在这个时节一定要遵从医嘱，规律用药。 中新网12月19日电 国家卫生健康委19日召开新闻发布会，介绍时令节气与健康(冬至)有关情况。针对很 多人受寒后容易久咳不愈的情况，中国中医科学院望京医院主任医师高峰在会上表示，很多人在受寒感 冒后会出现咳嗽、咽痒这种症状，日久不能恢复，主要的原因是感冒后气道上皮受损，尚没有完全修 复，气道的敏感性就会增强，受到一点刺激就会诱发咳嗽。中医认为，这是外感后的正气还没有完全恢 复的表现。 高峰称，如果咳嗽 ...

来源：新浪证券-红岸工作室 12月19日，采纳股份跌0.28%，成交额4770.88万元，换手率2.26%，总市值34.28亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 该股筹码平均交易成本为27.84元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近支撑位 27.70，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 公司简介 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 采纳股份所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：融资融券 ...

Group 1 - The core viewpoint of the articles highlights the air quality forecast for Beijing, indicating a potential level 4 moderate pollution from December 18 to 19, 2025, and the initiation of a yellow alert for air pollution [1] - The Beijing CDC advises the public to take health precautions during this period of air pollution [1] Group 2 - Acute health hazards from heavy pollution include symptoms such as cough, sore throat, and eye irritation, and can exacerbate chronic diseases like asthma and cardiovascular conditions [2] - Chronic health risks associated with long-term exposure to heavy pollution include increased incidence of respiratory diseases and cardiovascular issues, as noted by the World Health Organization [2] Group 3 - During heavy pollution events, individuals are advised to minimize exposure by staying indoors, especially vulnerable groups such as children, pregnant women, the elderly, and those with pre-existing health conditions [4] - Schools are encouraged to reduce outdoor activities based on local air quality conditions [5] Group 4 - Recommendations for indoor air quality include closing windows, avoiding smoking indoors, and minimizing activities that may worsen indoor air pollution [5] - The use of air purification devices is suggested to lower indoor pollutant concentrations during heavy pollution [11] Group 5 - Proper mask selection and usage are emphasized to mitigate health impacts from pollution, with a recommendation to use masks that meet GB/T 32610-2016 standards [7] - It is important to ensure a good fit of the mask to the face to prevent air leakage [8] Group 6 - Guidelines for using air purifiers include keeping rooms as sealed as possible and ensuring that the purifier is not obstructed [12] - Air purifiers should be operated at high settings initially for rapid air purification, followed by a quieter setting to maintain air quality [13]

Group 1 - The core viewpoint of the news is that Lanzhou Foci Pharmaceutical Co., Ltd. has experienced fluctuations in stock price and trading activity, with a year-to-date increase of 14.56% and a recent trading volume indicating mixed investor sentiment [1][2] - As of December 19, the stock price reached 8.83 yuan per share, with a market capitalization of 4.509 billion yuan and a trading volume of 19.7244 million yuan [1] - The company has seen a net outflow of main funds amounting to 827,200 yuan, with significant buying and selling activity from large orders [1] Group 2 - Lanzhou Foci Pharmaceutical was established on June 28, 2000, and listed on December 22, 2011, focusing on the research, production, and sales of traditional Chinese medicine and health products [2] - The company's main business revenue composition includes 99.41% from traditional Chinese medicine, medicinal materials, and protective products, with minor contributions from packaging materials and health foods [2] - As of September 30, the number of shareholders increased to 33,300, with an average of 15,340 circulating shares per person, indicating a slight decrease in individual shareholding [2] Group 3 - The company has distributed a total of 180 million yuan in dividends since its A-share listing, with 46.9804 million yuan distributed over the past three years [3]

Core Viewpoint - The company, Canar Medical, has shown a slight increase in stock price and is benefiting from the depreciation of the RMB, particularly in its overseas revenue which constitutes a significant portion of its business [1][3]. Group 1: Company Overview - Canar Medical was established on July 23, 2004, and went public on January 26, 2022. The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The main revenue components of Canar Medical include syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of November 28, the number of shareholders in Canar Medical is 8,801, a decrease of 2.05% from the previous period, while the average circulating shares per person increased by 2.09% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86%. The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On December 18, Canar Medical's stock price increased by 0.43%, with a trading volume of 46.28 million yuan and a turnover rate of 2.17%, resulting in a total market capitalization of 3.44 billion yuan [1]. - The company has been experiencing a net outflow of funds, with a net outflow of 1.05 million yuan on the day of the report, indicating a lack of strong market support [4][5]. Group 4: Technical Analysis - The average trading cost of Canar Medical's shares is 27.83 yuan, with the stock price currently near a support level of 27.75 yuan. There are indications of accumulation, but the strength of this accumulation is weak [6].

Group 1 - The three major indices showed mixed performance, with the Shanghai Composite Index up 0.16%, while the Shenzhen Component Index and the ChiNext Index fell by 1.29% and 2.17% respectively, with a total trading volume of approximately 1.66 trillion yuan [2] - The pharmaceutical retail sector saw a resurgence, with companies like Huaren Health and Shuyuan Pingmin rising by 20%, and Yixin Tang increasing by 10%, indicating strong market interest [2] - Ant Group announced an upgrade of its AI health application to "Ant Ai Fu," focusing on a "health+" strategy, which aims to assist users in managing their health like a personal friend [2] Group 2 - The commercial aerospace sector remains active, with Tianyin Electromechanical rising over 16% and Aerospace Huanyu increasing by 14.71%, reflecting investor confidence in the industry [3] - The Long March 12A reusable rocket, developed by China Aerospace Science and Technology Corporation, is set for its historic first launch in December 2025, marking a significant milestone in China's space endeavors [3] - A report from Huaxi Securities highlights a shift in the commercial aerospace sector towards reusable manufacturing, with companies like SpaceX leading the way in reducing costs through increased reuse and launch frequency [3] Group 3 - The Central Economic Work Conference emphasized expanding domestic demand as a top priority for 2025, focusing on structural changes in consumption to stimulate growth [4] - Bank stocks performed well, with Shanghai Bank, Chongqing Rural Commercial Bank, and Suzhou Bank showing positive movements, indicating investor confidence in the banking sector [4] Group 4 - CICC's report forecasts that listed banks will see revenue growth rates of 2.5% and 3.6% for 2026 and 2027 respectively, with net profit growth rates of 1.9% and 2.6% [5] - The battery, AI, and PCB sectors experienced collective declines, with companies like Huasheng Lithium Battery dropping over 10%, indicating potential challenges in these industries [5] - Other sectors such as brokerage, automotive, liquor, and semiconductors also faced downturns, with notable declines in stocks like Muxi and BYD [5]